FDA OKs Voluven for post-op blood loss

Dec 28, 2007

The U.S. Food and Drug Administration has approved Voluven as a treatment for blood loss after surgery.

Voluven is an intravenous solution that expands blood volume, the agency said Thursday in a release.

Significant blood loss can cause a rapid drop in the volume of red blood cells and plasma circulating through the body. This can lead to shock, which is potentially fatal.

Blood volume expanders are commonly administered to restore quickly some of the lost volume so remaining red blood cells can continue to deliver needed oxygen to the body's tissues, the FDA said.

Voluven, made by the German-firm Fresenius Kabi, contains a synthetic starch that does not dissolve in water. It was found in clinical trials to be as safe and effective as other blood volume expanders, the agency said.

The most common side effects from Voluven were nausea and itching.

Copyright 2007 by United Press International

Explore further: Drug prices to treat multiple sclerosis soar, point to larger problem

Related Stories

Magnitude 6.7 aftershock hits Nepal, causes panic

24 minutes ago

A powerful aftershock shook Nepal on Sunday, making buildings sway and sending panicked Kathmandu residents running into the streets a day after a massive earthquake left at least 1,900 people dead.

Nepal quake: Nearly 1,400 dead, Everest shaken (Update)

10 hours ago

Tens of thousands of people were spending the night in the open under a chilly and thunderous sky after a powerful earthquake devastated Nepal on Saturday, killing nearly 1,400, collapsing modern houses and ...

Russian hackers read Obama emails, report says

10 hours ago

Emails to and from President Barack Obama were read by Russian hackers last year in a breach of the White House's unclassified computer system, The New York Times said Saturday.

Supermarkets welcome cold-comfort edge of F1 aerofoils

15 hours ago

UK-based Williams Advanced Engineering, the technology and engineering services business of the Williams Group, has collaborated with UK-based Aerofoil Energy to develop an aerodynamic device that can reduce ...

Recommended for you

Mylan rebuffs Teva again; calls bid low, insincere

10 hours ago

Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.

Rising antibiotic shortages raise concerns about patient care

Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.